In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other S&P 500 stocks. As per AXA Investment Managers, the US dominated financial markets this ...

Eli Lilly (NYSE: LLY) stock tanked after the company reported third-quarter results on Wednesday, Oct. 30. The report it issued before the opening bell was more than a little problematic.

What would a Harris or Trump presidency mean for health care policy? Why did Eli Lilly’s Mounjaro and Zepbound sales miss expectations? And does Adam believe in ghosts? We talk about all that an ...

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE: LLY) has had a strong run this year, up more than 55%. However, the company's success goes back much further, with the ...

NOTE: Numbers on this page are based on expenditures reported by candidates, parties, PACs and outside spending groups for the 2021-2022 election cycle, based on Federal Election Commission data ...

GRAND FORKS — Technically, Eli McKamey is too young to play in the British Columbia Hockey League. He's only 15. But last spring, the BCHL made an exception for the first time in league history.

Why has this year’s presidential race been such an unnerving spectacle? It has been bitterly partisan and rhetorically unhinged—but so was the 1800 contest between Thomas Jefferson and John ...

Those who follow my work closely know that I have been a big fan of pharmaceutical firm Eli Lilly and Company (NYSE:LLY) for a little while now. My first article about the company, published in ...

Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets with new data readouts. J&J evaluated its Tremfya in patients with low ...

With no clear leader in the presidential election according to the most recent CNN Poll of Polls, the battle for Congress will be crucial to determining whether Kamala Harris or Donald Trump will ...

Citi raised the firm’s price target on Eli Lilly (LLY) to $1,250 from $1,060 and keeps a Buy rating on the shares following a transfer of analyst coverage. GLP-1 adoption has fueled Lilly’s ...